<DOC>
	<DOCNO>NCT00391729</DOCNO>
	<brief_summary>The objective study compare safety efficacy five dos ABT-089 ( 2 mg QD , 5 mg QD , 15 mg QD , 40 mg QD 40 mg BID ) placebo adult ADHD .</brief_summary>
	<brief_title>A Dose-Ranging , Cross-over Study Safety Efficacy ABT-089 Adults With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Meet criterion attention deficit hyperactivity disorder Have voluntarily sign informed consent form Are 18 60 year age Will use contraceptive method study Women must pregnant breastfeeding Must generally good health Are fluent English They current past diagnosis schizoaffective disorder , schizophrenia , obsessivecompulsive disorder , druginduced psychosis , bipolar disorder , psychotic disorder mental retardation They current diagnosis major depressive episode , generalize anxiety disorder ( GAD ) , posttraumatic stress disorder ( PTSD ) clinically significant sleep disorder require treatment They require ongoing treatment expect treatment psychotropic medication , include anxiolytic , antipsychotic , anticonvulsant , antidepressant mood stabilizer They fail respond two adequate trial FDAapproved ADHD medication They violent , homicidal suicidal ideation They significant history medical diagnosis , seizure disorder , Tourette 's syndrome central nervous system ( CNS ) disease , exclude ADHD They urine drug screen positive alcohol drug abuse They history substance alcohol disorder ( abuse/dependence ) last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ADHD</keyword>
</DOC>